Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17077860 | 0.84 | NPC1 (0.55) | RAB9ANPC1TTBK1TTBK2MAPT | |
| SCHEMBL1600224 | 0.80 | MAPT (0.43) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL17077800 | 0.79 | SYK (0.46) | RAB9ANPC1TTBK1TTBK2MAPT | |
| SCHEMBL17077895 | 0.78 | MAPT (0.53) | RAB9ANPC1MAPTHTTNPSR1 | |
| SCHEMBL13730057 | 0.76 | BCL6 (0.51) | MAPTHTTALDH1A1LMNAMEN1 | |
| SCHEMBL6803840 | 0.75 | CA12 (0.58) | RAB9ANPC1TTBK1TTBK2MAPT | |
| SCHEMBL3998429 | 0.73 | NPC1 (0.57) | RAB9ANPC1MAPTHTTNPSR1 | |
| SCHEMBL31227501 | 0.71 | ABL1 (0.44) | TTBK1TTBK2MAPTALDH1A1KDM4E | |
| SCHEMBL6906973 | 0.71 | RAB9A (0.60) | RAB9ANPC1MAPTHTTNPSR1 | |
| SCHEMBL38657018 | 0.70 | TYK2 (0.39) | NPC1MAPTHTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116858-B1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2020-11-11 | — | — | EP | disclosed |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2018-11-29 | — | — | US | disclosed |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-3116858-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| WO-2015136947-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | RAB9A 1225/4885NPC1 459/4885TTBK1 2353/4885 |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | TRPM8, TRPM7, TRPM5 | RAB9A 1225/4885NPC1 459/4885TTBK1 2353/4885 |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM6 | RAB9A 1184/4885NPC1 421/4885TTBK1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.